Drug Trial Radar · NCT02600507
Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression
Last checked: Nov 20, 2026Latest source record: May 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
529
Actual
Start
Mar 7, 2016
Primary completion
Jul 2, 2020
Study completion Jul 2, 2020
Sponsor
- Lead sponsor
- Intra-Cellular Therapies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the efficacy and safety of ITI-007 adjunctive to lithium or valproate in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode.
Conditions
- Bipolar Depression
Interventions
Lumateperone (ITI-007)Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total ScoreTime frame: Baseline to Day 43
Locations
71 sites in 5 countries. Site status is shown where the registry gives one.
Clinical Site
Rogers, Arkansas
Clinical Site
Cerritos, California
Clinical Site
Costa Mesa, California
Clinical Site
Culver City, California
Clinical Site
Garden Grove, California
Clinical Site
Glendale, California
Clinical Site
Lemon Grove, California
Clinical Site
Oceanside, California
Clinical Site
Pico Rivera, California
Clinical Site
Riverside, California
Clinical Site
San Diego, California
Clinical Site
Santa Rosa, California
Clinical Site
Sherman Oaks, California
Clinical Site
Temecula, California
Clinical Site
Jacksonville, Florida
Clinical Site
Lauderhill, Florida
Clinical Site
Miami, Florida
Clinical Site
Orange City, Florida
Clinical Site
Orlando, Florida
Clinical Site
Atlanta, Georgia
Clinical Site
Savannah, Georgia
Clinical Site
Chicago, Illinois
Clinical Site
Lake Charles, Louisiana
Clinical Site
Baltimore, Maryland
Clinical Site
O'Fallon, Missouri
Clinical Site
St Louis, Missouri
Clinical Site
Las Vegas, Nevada
Clinical Site
Berlin, New Jersey
Clinical Site
Cherry Hill, New Jersey
Clinical Site
Toms River, New Jersey
Clinical Site
Cedarhurst, New York
Clinical Site
New York, New York
Clinical Site
Rochester, New York
Clinical Site
Staten Island, New York
Clinical Site
Charlotte, North Carolina
Clinical Site
Cincinnati, Ohio
Clinical Site
Dayton, Ohio
Clinical Site
Garfield Heights, Ohio
Clinical Site
Allentown, Pennsylvania
Clinical Site
Philadelphia, Pennsylvania
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.